Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection
暂无分享,去创建一个
[1] V. Castranova,et al. JNK1, a potential therapeutic target for hepatocellular carcinoma. , 2009, Biochimica et biophysica acta.
[2] S. Harrison,et al. NASH and HCC. , 2009, Clinics in liver disease.
[3] S. Caldwell,et al. Epidemiology and natural history of non-alcoholic steatohepatitis. , 2009, Clinics in liver disease.
[4] K. Shimada,et al. Short-term 20-mg atorvastatin therapy reduces key inflammatory factors including c-Jun N-terminal kinase and dendritic cells and matrix metalloproteinase expression in human abdominal aortic aneurysmal wall. , 2009, Atherosclerosis.
[5] V. Alves,et al. Does hepatocellular carcinoma in non-alcoholic steatohepatitis exist in cirrhotic and non-cirrhotic patients? , 2009, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.
[6] Y. Hiasa,et al. Diabetes pattern on the 75 g oral glucose tolerance test is a risk factor for hepatocellular carcinoma in patients with hepatitis C virus , 2009, Liver international : official journal of the International Association for the Study of the Liver.
[7] Michael L. Johnson,et al. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. , 2009, Gastroenterology.
[8] V. Castranova,et al. Beyond apoptosis of JNK1 in liver cancer , 2009, Cell cycle.
[9] P. Micheli,et al. Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steato-hepatitis. , 2009, Journal of hepatology.
[10] Chunhong Bai,et al. Long-term follow-up of patients with nonalcoholic fatty liver. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[11] Xianglin Shi,et al. Sustained JNK1 activation is associated with altered histone H3 methylations in human liver cancer. , 2009, Journal of hepatology.
[12] A. Pietrangelo. Iron in NASH, chronic liver diseases and HCC: how much iron is too much? , 2009, Journal of hepatology.
[13] H. Nakagawa,et al. Visceral fat accumulation is an independent risk factor for hepatocellular carcinoma recurrence after curative treatment in patients with suspected NASH , 2009, Gut.
[14] M. Czaja,et al. Differential effects of JNK1 and JNK2 inhibition on murine steatohepatitis and insulin resistance , 2009, Hepatology.
[15] M. Taniai,et al. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis , 2009, Journal of Gastroenterology.
[16] S. Caldwell,et al. The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology , 2009, Journal of Gastroenterology.
[17] E. Wagner,et al. Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. , 2008, The Journal of clinical investigation.
[18] G. Chejfec,et al. Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis? , 2008, Archives of pathology & laboratory medicine.
[19] Z. Younossi,et al. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. , 2008, Journal of hepatology.
[20] S. Taylor-Robinson,et al. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. , 2008, World journal of gastroenterology.
[21] N. Kato,et al. Obesity is an independent risk factor for hepatocellular carcinoma development in chronic hepatitis C patients. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[22] Ramesh Natarajan,et al. Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. , 2008, Gastroenterology.
[23] Z. Younossi,et al. 6 NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IS ASSOCIATED WITH HIGHER OVERALL MORTALITY AND LIVER RELATED MORTALITY , 2008 .
[24] M. Ziol,et al. Liver iron, HFE gene mutations, and hepatocellular carcinoma occurrence in patients with cirrhosis. , 2008, Gastroenterology.
[25] A. McCullough. The Epidemiology and Risk Factors of NASH , 2007 .
[26] M. Mori,et al. Primary liver cancers with nonalcoholic steatohepatitis , 2007, European journal of gastroenterology & hepatology.
[27] H. El‐Serag,et al. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. , 2007, Gastroenterology.
[28] S. Ikeya,et al. [Two cases of patients with hepatocellular carcinoma (HCC) that developed in cryptogenic cirrhosis suggestive of nonalcoholic steatohepatitis (NASH) as background liver disease after clinical courses of 26 years]. , 2007, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology.
[29] T. Luedde,et al. Deletion of NEMO/IKKγ in Liver Parenchymal Cells Causes Steatohepatitis and Hepatocellular Carcinoma , 2007 .
[30] Z. Younossi,et al. Epidemiology and natural history of NAFLD and NASH. , 2007, Clinics in liver disease.
[31] E. Bugianesi,et al. Non-alcoholic steatohepatitis and cancer. , 2007, Clinics in liver disease.
[32] Kenichi Kobayashi,et al. Clinicopathologic study of alcohol-like liver disease in non-alcoholics; non-alcoholic steatohepatitis and fibrosis , 1992, Gastroenterologia Japonica.
[33] T. Luedde,et al. Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. , 2007, Cancer cell.
[34] K. Eguchi,et al. Two cases of non‐alcoholic steatohepatitis with development of hepatocellular carcinoma without cirrhosis , 2006, Journal of gastroenterology and hepatology.
[35] M. Holmqvist,et al. Long‐term follow‐up of patients with NAFLD and elevated liver enzymes , 2006, Hepatology.
[36] T. Saibara,et al. 7. 非アルコール性脂肪肝炎 (NASH) の診断と治療 , 2006 .
[37] M. Karin,et al. Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[38] Y. Maehara,et al. Deletion of the SOCS3 gene in liver parenchymal cells promotes hepatitis-induced hepatocarcinogenesis. , 2006, Gastroenterology.
[39] M. Czaja,et al. Jnk1 but not jnk2 promotes the development of steatohepatitis in mice , 2006, Hepatology.
[40] Tetsuji Sato,et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. , 2006, Annals of internal medicine.
[41] D. Schuppan,et al. EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer. , 2005, Biochemical pharmacology.
[42] Shi-yao Chen,et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. , 2005, Journal of hepatology.
[43] Y. Ueda,et al. Hepatocellular carcinoma and nonalcoholic steatohepatitis developing during long-term administration of valproic acid , 2005, Virchows Archiv.
[44] Y. Yoon,et al. Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] S. Sanderson,et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. , 2005, Gastroenterology.
[46] G. Bedogni,et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos nutrition and liver study , 2005, Hepatology.
[47] Candy S. Lee,et al. Liver-specific inactivation of the Nrf1 gene in adult mouse leads to nonalcoholic steatohepatitis and hepatic neoplasia. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[48] J. Crespo,et al. Non-alcoholic Steatohepatitis (NASH) and Hepatocellular Carcinoma , 2005, Obesity surgery.
[49] M. Manos,et al. Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease , 2005, Hepatology.
[50] A. Suzuki,et al. Chronological development of elevated aminotransferases in a nonalcoholic population , 2005, Hepatology.
[51] S. Sanderson,et al. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. , 2005, Journal of hepatology.
[52] David A. Sass,et al. Nonalcoholic Fatty Liver Disease: A Clinical Review , 2005, Digestive Diseases and Sciences.
[53] K. Wakasa,et al. Hepatocellular Carcinoma Arising from Nonalcoholic Steatohepatitis: Report of Two Cases , 2005, Surgery Today.
[54] Jonathan C. Cohen,et al. Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity , 2004, Hepatology.
[55] M. Taniai,et al. Nonalcoholic steatohepatitis: cirrhosis, hepatocellular carcinoma, and burnt-out NASH , 2004, Journal of Gastroenterology.
[56] S. Caldwell,et al. Obesity and hepatocellular carcinoma. , 2004, Gastroenterology.
[57] Josepa Ribes,et al. Primary liver cancer: worldwide incidence and trends. , 2004, Gastroenterology.
[58] D. Lobo,et al. Association of non-alcoholic steatohepatitis without significant fibrosis with hepatocellular carcinoma. , 2004, Journal of hepatology.
[59] E. Fassio,et al. Natural history of nonalcoholic steathepatitis: A longitudinal study of repeat liver biopsies , 2004, Hepatology.
[60] E. Calle,et al. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms , 2004, Nature Reviews Cancer.
[61] A. Luciani,et al. Carcinome hépatocellulaire en l’absence de cirrhose au cours d’une stéato-hépatite non alcoolique , 2004 .
[62] L. Burgart,et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial , 2004, Hepatology.
[63] S. Kihara,et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[64] H. El‐Serag,et al. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. , 2004, Gastroenterology.
[65] E. Abdalla,et al. Obesity and diabetes as a risk factor for hepatocellular carcinoma , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[66] A. Luciani,et al. [Hepatocellular carcinoma without cirrhosis in a patient with nonalcoholic steatohepatitis]. , 2004, Gastroenterologie clinique et biologique.
[67] H. Adami,et al. A prospective study of obesity and cancer risk (Sweden) , 2004, Cancer Causes & Control.
[68] John K. Wiencke,et al. Impact of race/ethnicity on molecular pathways in human cancer , 2004, Nature Reviews Cancer.
[69] Teruaki Kimura,et al. Hepatocellular carcinoma with nonalcoholic steatohepatitis , 2004, Journal of Gastroenterology.
[70] P. Hayashi,et al. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study , 2003, American Journal of Gastroenterology.
[71] James G Kench,et al. Long‐term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C , 2003, Hepatology.
[72] K. Eguchi,et al. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection , 2003, Cancer.
[73] Jian-Gao Fan,et al. Prevalence of nonalcoholic fatty liver among administrative officers in Shanghai: an epidemiological survey. , 2003, World journal of gastroenterology.
[74] N. Kennedy,et al. Role of JNK in Tumor Development , 2003, Cell cycle.
[75] F. Brancati,et al. The prevalence and etiology of elevated aminotransferase levels in the United States , 2003, American Journal of Gastroenterology.
[76] Michael J Thun,et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. , 2003, The New England journal of medicine.
[77] G. Marchesini,et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome , 2003, Hepatology.
[78] Z. Younossi,et al. Nonalcoholic fatty liver disease (NAFLD) two decades later: are we smarter about its natural history? , 2003, American Journal of Gastroenterology.
[79] J. Marrero,et al. NAFLD may be a common underlying liver disease in patients with hepatocellular Carcinoma in the United States , 2002, Hepatology.
[80] Michael Karin,et al. A central role for JNK in obesity and insulin resistance , 2002, Nature.
[81] S. Lai,et al. Epidemiology of Fatty Liver in a Hospital-based Study in Taiwan , 2002, Southern medical journal.
[82] M. Tang,et al. The major lipid peroxidation product, trans-4-hydroxy-2-nonenal, preferentially forms DNA adducts at codon 249 of human p53 gene, a unique mutational hotspot in hepatocellular carcinoma. , 2002, Carcinogenesis.
[83] Hajime Isomoto,et al. Fatty liver in non‐alcoholic non‐overweight Japanese adults: Incidence and clinical characteristics , 2002, Journal of gastroenterology and hepatology.
[84] O. Ukkola,et al. Adiponectin: a link between excess adiposity and associated comorbidities? , 2002, Journal of Molecular Medicine.
[85] Mauro Salizzoni,et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. , 2002, Gastroenterology.
[86] G. Loss,et al. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? , 2002, Hepatology.
[87] J. Ludwig,et al. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. , 2002, Journal of hepatology.
[88] P. Giral,et al. Survival, liver failure, and hepatocellular carcinoma in obesity‐related cryptogenic cirrhosis , 2002, Hepatology.
[89] J. Patrie,et al. Is NASH underdiagnosed among African Americans? , 2002, American Journal of Gastroenterology.
[90] G. Pacini,et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: Further evidence for an etiologic association , 2002, Hepatology.
[91] R. Karim,et al. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome , 2002, Hepatology.
[92] D. Parkin,et al. Global cancer statistics in the year 2000. , 2001, The Lancet. Oncology.
[93] Z. Younossi,et al. Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease , 2001, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[94] L. Bianchi,et al. Liver biopsy in elevated liver functions tests? An old question revisited. , 2001, Journal of hepatology.
[95] P. D. James,et al. Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. , 2001, Journal of hepatology.
[96] H. El‐Serag,et al. The role of diabetes in hepatocellular carcinoma: a case-control study among United States veterans , 2001, American Journal of Gastroenterology.
[97] Y. Matsuzawa,et al. Hepatocellular Carcinoma (hcc) Causes Death in Patients with Cirrhosis and Is One of the Most Prevalent Malignant Tumours Effect of Pravastatin on Survival in Patients with Advanced Hepatocellular Carcinoma. a Randomized Controlled Trial , 2022 .
[98] K. Tsuneyama,et al. Hepatocellular carcinoma arising in non‐alcoholic steatohepatitis , 2001, Pathology international.
[99] K. Yamazaki,et al. Lipid-rich clear-cell hepatocellular carcinoma arising in non-alcoholic steatohepatitis in a patient with diabetes mellitus. , 2001, Journal of submicroscopic cytology and pathology.
[100] Sue Goo Rhee,et al. Hydrogen Peroxide: A Key Messenger That Modulates Protein Phosphorylation Through Cysteine Oxidation , 2000, Science's STKE.
[101] P. Thuluvath,et al. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: A case‐control study , 2000, Hepatology.
[102] R. Paraná,et al. Nonalcoholic steatohepatitis and hepatocellular carcinoma: natural history? , 2000, American Journal of Gastroenterology.
[103] H. Adami,et al. Role of diabetes mellitus in the etiology of hepatocellular carcinoma. , 2000, Journal of the National Cancer Institute.
[104] H. Zhu,et al. Mitochondrial adaptations to obesity-related oxidant stress. , 2000, Archives of biochemistry and biophysics.
[105] M. Blumenkehl. Response to Dr. Kirsch , 2000, American Journal of Gastroenterology.
[106] V. de Lédinghen,et al. Increased incidence of HFE C282Y mutations in patients with iron overload and hepatocellular carcinoma developed in non-cirrhotic liver. , 2000, Journal of hepatology.
[107] H. Cortez‐Pinto,et al. Non-alcoholic fatty liver: another feature of the metabolic syndrome? , 1999, Clinical nutrition.
[108] T. Ben-Menachem,et al. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients , 1999, American Journal of Gastroenterology.
[109] H. El‐Serag,et al. Rising incidence of hepatocellular carcinoma in the United States. , 1999, The New England journal of medicine.
[110] S. Caldwell,et al. Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease , 1999, Hepatology.
[111] H. Cortez‐Pinto,et al. Non-alcoholic fatty liver: another feature of the metabolic syndrome? , 1999, Clinical nutrition.
[112] P. Ward,et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. , 1998, Gastroenterology.
[113] M Linet,et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. , 1997, Journal of the National Cancer Institute.
[114] S. Finkelstein,et al. Loss of the gene encoding mannose 6-phosphate/insulin-like growth factor II receptor is an early event in liver carcinogenesis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[115] E. Schmidt,et al. Biological effects of human insulin receptor substrate‐1 overexpression in hepatocytes , 1997, Hepatology.
[116] C. Christoffersen,et al. Mitogenic properties of insulin and insulin analogues mediated by the insulin receptor , 1997, Diabetologia.
[117] H. Adami,et al. Excess risk of primary liver cancer in patients with diabetes mellitus. , 1996, Journal of the National Cancer Institute.
[118] Y. Ahn. Strategy for vaccination against hepatitis B in areas with high endemicity: focus on Korea. , 1996, Gut.
[119] G. Rassidakis,et al. Histopathology of chronic hepatitis C in relation to epidemiological factors. , 1996, Journal of hepatology.
[120] F. J. Farrell,et al. Primary liver cancer and survival in patients undergoing liver transplantation for hemochromatosis. , 1995, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[121] J. Ludwig,et al. Two cases from the spectrum of nonalcoholic steatohepatitis. , 1995, Journal of clinical gastroenterology.
[122] K. Ishak,et al. Histopathology of Hepatitis C Virus Infection , 1995, Seminars in liver disease.
[123] J. Olsen,et al. Obesity and cancer risk: a Danish record-linkage study. , 1994, European journal of cancer.
[124] A. Czaja,et al. Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis. , 1993, Gastroenterology.
[125] E. Schiff,et al. Pathological diagnosis of chronic hepatitis C: a multicenter comparative study with chronic hepatitis B. The Hepatitis Interventional Therapy Group. , 1993, Gastroenterology.
[126] S. Sherlock,et al. The pathology of hepatitis C , 1992, Hepatology.
[127] F. Schaffner,et al. The histological features of chronic hepatitis C and autoimmune chronic hepatitis: A comparative analysis , 1992, Hepatology.
[128] B. Cesana,et al. Surival and prognostic factors in 212 Italian patients with genetic hemochromatosis , 1992, Hepatology.
[129] R. Hanson,et al. The natural history of nonalcoholic steatohepatitis: A follow‐up study of forty‐two patients for up to 21 years , 1990, Hepatology.
[130] H. Nomura,et al. Prevalence of fatty liver in a general population of Okinawa, Japan. , 1988, Japanese journal of medicine.
[131] F. Schaffner,et al. Nonalcoholic fatty liver disease. , 1986, Progress in liver diseases.
[132] Ground Ke. Liver pathology in aircrew. , 1982 .
[133] K. E. Ground. Liver pathology in aircrew. , 1982, Aviation, space, and environmental medicine.
[134] C P Price,et al. Liver disease in patients with diabetes mellitus. , 1980, Postgraduate medical journal.
[135] J. Ludwig,et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. , 1980, Mayo Clinic proceedings.
[136] L. Garfinkel,et al. Variations in mortality by weight among 750,000 men and women. , 1979, Journal of chronic diseases.
[137] P. Christoffersen,et al. Liver histology in a 'normal' population--examinations of 503 consecutive fatal traffic casualties. , 1977, Scandinavian journal of gastroenterology.